ARD-101 shows strong efficacy signals including reduction of hunger and body fat composition in the treatment of Prader-Willi Syndrome, a rare genetic disease.
E-Mail
New research presented at this year s European Congress on Obesity (held online, 10-13 May) shows that the obesity drug semaglutide reduces appetite, food cravings and energy intake in people given a meal where they could eat as much as they liked. The study is by Dr Dorthe Skovgaard, Novo Nordisk A/S (the manufacturer of the drug), Søborg, Denmark, and colleagues.
Semaglutide, in the glucagon-like peptide-1 (GLP-1) analogue drug class, is currently available at the dose of 1.0 mg injected once weekly for the treatment of type 2 diabetes and is under development for chronic weight management at the dose 2.4 mg injected once weekly. It is currently not approved for obesity anywhere in the world, however new drug applications are under review by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other health agencies across the world.